Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes and Circulating Biomarkers Summit 2013

Johan Skog's Biography



Johan Skog, Chief Scientific Officer, Exosome Diagnostics Inc

Dr. Skog currently serves as chief scientific officer of Exosome Diagnostics where he is leading the research and development efforts for biofluid diagnostics using exosomes in diseases such as cancer, metabolic and neurodegenerative diseases. He is the primary inventor of Exosome Diagnostics' core technology and, in particular, blood-based genetic diagnostics of cancer. Dr. Skog made the discovery that tumor-shed exosomes (microvesicles) contain genetic information of the tumor. He showed that these microvesicles serve to deliver messages to other cells inducing changes favorable to the proliferation of cancer cells. He demonstrated that these tumor exosomes are released into the bloodstream and that they can be isolated and studied for genetic mutations (Skog et al. Nature Cell Biology 2008; 10: 1470-1476). Prior to the start of the company Exosome Diagnostics, Dr. Skog was working at Massachusetts General Hospital/Harvard Medical School where he was studying the role of tumor stem cells in gliomas and later tumor derived exosomes, including their content of RNA biomarkers and transposable elements such as endogenous retroviruses. He also showed that gene therapy vectors can be incorporated into microvesicles and be used as a “stealth” vector with changed tropisms (Maguire et al. Molecular Therapy 2012 Feb 7). Dr. Skog received his PhD at the Department of Virology, Umea University, Sweden, working on novel gene therapy vectors for treatment of gliomas.

Johan Skog Image

Microvesicle (exosome) RNA as Biomarkers for Disease

Thursday, 12 September 2013 at 09:00

Add to Calendar ▼2013-09-12 09:00:002013-09-12 10:00:00Europe/LondonMicrovesicle (exosome) RNA as Biomarkers for DiseaseExosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com

Microvesicles (exosomes) are released from all cells and can be isolated from biofluids, including serum, plasma, urine, and CSF. These exosomes carry RNA (mRNA, microRNA, and other small RNAs) and protein from the donor cell that can be easily isolated even after long-term storage in freezers. The use of exosomal RNA has sparked a tremendous interest in the field of biomarkers, where access to the genetic status of disease in a non-invasive way is highly desirable. To develop a clinical test using microvesicle RNA, isolation of exosomes in a robust way that is easy, scalable, reproducible and allows for high-throughput processing in a clinical setting is critical. The RNA needs to be of high quality with markers that allow quality assessment of clinical samples. The use of exosomes is a great platform that enables longitudinal monitoring of a variety of mutations and transcript levels in tumors using qPCR, NGS and digital PCR.


Add to Calendar ▼2013-09-12 00:00:002013-09-13 00:00:00Europe/LondonExosomes and Circulating Biomarkers Summit 2013Exosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com